Xbrane Joins Forces With Contract Manufacturer For Cimzia Biosimilar
Danish Firm AGC Biologics Will Assist Swedish Player Ahead Of Clinical Trials
Sweden’s Xbrane Biopharma has secured a manufacturing partner in its native Scandinavia, Denmark’s AGC Biologics, to help complete key steps for its proposed Xcimzane (certolizumab pegol) biosimilar to Cimzia ahead of Phase I and Phase III clinical trials.
